Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-54861911-Therapeutic Dose · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment Sequence Group ADBC | EXPERIMENTAL | Participant will receive Treatment A (JNJ-54861911, 50 milligram (mg) once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of second treatment regimen, then Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen). |
| Treatment Sequence Group BACD | EXPERIMENTAL | Participant will receive Treatment B (JNJ-54861911, 150 mg once daily for 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by followed by Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of fourth treatment regimen). |
| Treatment Sequence Group CBDA | EXPERIMENTAL | Participant will receive Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on second treatment regimen), then Treatment D (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin 400 mg on Day 7 of third treatment regimen) followed by Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of fourth treatment regimen). |
| Treatment Sequence Group DCAB | EXPERIMENTAL | Participant will receive Treatment D (JNJ-54861911-matched placebo once daily for 7 days plus moxifloxacin 400 mg on Day 7) followed by Treatment C (JNJ-54861911-matched placebo once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of second treatment regimen), then Treatment A (JNJ-54861911, 50 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 of third treatment regimen) followed by Treatment B (JNJ-54861911, 150 mg once daily for next 7 days plus moxifloxacin-matched placebo on Day 7 on fourth treatment regimen). |
| Name | Type | Description |
|---|---|---|
| JNJ-54861911-Therapeutic Dose | DRUG | JNJ-54861911 50 mg once daily for 7 days in all treatment sequence. |
| JNJ-54861911 - Supratherapeutic Dose | DRUG | JNJ-54861911 150 mg once daily for 7 days in all treatment sequence. |
| JNJ-54861911-Matched Placebo | DRUG | JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence. |
| Moxifloxacin | DRUG | Moxifloxacin 400 mg on Day 7 in all treatment sequence. |
| Moxifloxacin Matched Placebo | DRUG | Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence. |
Inclusion Criteria: * Signed an informed consent document indicating they understand the purpose of and procedures required for the study, including the required pharmacogenomics component (which specifies testing of genes predisposing to long or short QT and related cardiac syndromes), and are wil...
JNJ-54861911-Therapeutic Dose is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in Phase 1 clinical development. The single completed trial evaluated its effects on electrocardiogram intervals in healthy participants, indicating a focus on cardiac safety assessment.
Johnson & Johnson (NYSE: JNJ) is developing JNJ-54861911-Therapeutic Dose. The company sponsored the Phase 1 clinical trial of this investigational small molecule, which is being studied in healthy volunteers.
JNJ-54861911-Therapeutic Dose is in Phase 1 clinical development. It is an investigational drug, not yet approved, and has completed one Phase 1 trial in healthy volunteers. The trial was randomized, double-blind, and controlled, with 64 participants enrolled.
JNJ-54861911-Therapeutic Dose has one completed clinical trial, NCT02152332, titled "A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Participants." This Phase 1 study enrolled 64 healthy adults in the United States and was randomized, double-blind, and controlled.
JNJ-54861911-Therapeutic Dose is not FDA approved. It is an investigational small molecule in Phase 1 clinical development. The only completed trial, NCT02152332, was a safety study in healthy volunteers, and the drug remains under investigation.